(Yicai Global) Aug. 17 -- Chinese healthcare group Shanghai Fosun Pharmaceutical (Group) Co. [SHA:600196] and Medidata Solutions Inc., a world-leading global medical software company, reached a cooperation agreement to raise the operational efficiency of its clinical studies in China.

Medidata announced an enterprise agreement with Shanghai Fosun Pharmaceutical Development Co., a subsidiary of Fosun Pharma will adopt the Medidata Clinical Cloud platform to improve data management capabilities and enhance the operational efficiency of its clinical studies, cs.com.cn reported.

Medidata's cloud platform includes integrated electronic data acquisition (EDC) and clinical data management systems (CDMS) that efficiently collects, manages and reports patient data. Fosun medicine will rely on this technology to accelerate its as cardiovascular, oncology, anti-infection and central nervous system diseases.

Founded in 1999, Medidata is headquartered in New York, US. As of 2015, it had a workforce of 1,500 employees around the world and over 600 clients. Its cloud technology platform Medidata Clinical Cloud has supported over 10,000 clinical trials and 2.7 million test volunteers.